Webinar: How to thrive as a new public biotech

You have managed to lead your finance organization through multiple rounds of private funding. You have supported your executives as they navigate the harrowing path of bringing a drug candidate out of the lab and into clinical trials. Now you are looking at raising capital in the public markets to continue to support that growth. Are you ready? Is your team ready? Are your accounting systems ready?

In this webinar we help Controllers, VPs of Finance and other finance team members grapple with these questions. We will cover:

  • What it costs to bring your first drug to market
  • How your peers raise that required capital
  • When to start building your processes and people to meet the requirements for accessing public markets
  • When you should move from an accounting system to an ERP like Oracle NetSuite
  • What to expect when implementing an ERP as a small company
  • How you, as a leader in your organization, can ensure that your team survives the process and thrives as a public company

Featured Speakers

Steve Kemler

NetSuite Director and Life Sciences Senior Analyst


In May 2020, Steve was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves. These senior analysts advise clients on conditions influencing middle market leaders. Steve’s focus is on the life sciences industry.

Kyle Mandala

Consulting Manager


Kyle has assisted Life Sciences organizations with their technology transformations for 8 years. He is a key member of RSM’s Life Sciences team nationally and the Southwest market. Projects he has led range from pre-revenue organizations to commercialized entities, and exits.

Date:  Thursday, November 18, 2021
Time:  1pm ET / 10am PT
Duration:  1 Hour

Now Available On-Demand

© 2021 Questex LLC, All right reserved.

685 Third Avenue, 21st Floor New York, NY 10017

Reproduction in whole or part is prohibited.